[S02DA03, antipyrine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Prazosin.]
[M01AB02, sulindac, The therapeutic efficacy of Prazosin can be decreased when used in combination with Sulindac.]
[M01AX04, apazone, The therapeutic efficacy of Prazosin can be decreased when used in combination with Azapropazone.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Prazosin.]
[N05AE05, lurasidone, Prazosin may increase the hypotensive activities of Lurasidone.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Prazosin is combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Prazosin is combined with Thalidomide.]
[A11DA01, thiamine, The serum concentration of Prazosin can be increased when it is combined with Thiamine.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Prazosin.]
[N05AB08, thioproperazine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.]
[N05AC02, thioridazine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioridazine.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Prazosin.]
[S01ED01, timolol, The risk or severity of hypotension can be increased when Prazosin is combined with Timolol.]
[M02AX02, tolazoline, The risk or severity of hypotension can be increased when Prazosin is combined with Tolazoline.]
[M02AA21, tolmetin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Tolmetin.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Prazosin.]
[N06AX05, trazodone, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Prazosin is combined with Tretinoin.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Prazosin.]
[C03AA06, trichlormethiazide, The risk or severity of hypotension can be increased when Prazosin is combined with Trichlormethiazide.]
[N05AB06, trifluoperazine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[A03AA05, trimebutine, The risk or severity of hypotension can be increased when Prazosin is combined with Trimebutine.]
[S01ED04, metipranolol, Prazosin may increase the hypotensive activities of Metipranolol.]
[N03AC02, trimethadione, The risk or severity of hypotension can be increased when Prazosin is combined with Trimethadione.]
[C02BA01, trimethaphan, The risk or severity of hypotension can be increased when Prazosin is combined with Trimethaphan.]
[J01EA01, trimethoprim, The serum concentration of Prazosin can be increased when it is combined with Trimethoprim.]
[N06AA06, trimipramine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trimipramine.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Prazosin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hypotension can be increased when Prazosin is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Prazosin is combined with Tubocurarine.]
[L01EX04, vandetanib, Vandetanib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[A10BH05, linagliptin, The serum concentration of Prazosin can be increased when it is combined with Linagliptin.]
[J05AG05, rilpivirine, Rilpivirine may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Prazosin.]
[C08DA01, verapamil, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.]
[C04AX07, vincamine, The risk or severity of hypotension can be increased when Prazosin is combined with Vincamine.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Prazosin.]
[C03BA10, xipamide, The risk or severity of hypotension can be increased when Prazosin is combined with Xipamide.]
[N05AF05, zuclopenthixol, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[J05AE02, indinavir, The risk or severity of adverse effects can be increased when Indinavir is combined with Prazosin.]
[L01EC01, vemurafenib, Vemurafenib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Prazosin can be increased when it is combined with Crizotinib.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N05AE04, ziprasidone, Ziprasidone may increase the antihypertensive activities of Prazosin.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the antihypertensive activities of Prazosin.]
[C07AB03, atenolol, The risk or severity of hypotension can be increased when Prazosin is combined with Atenolol.]
[L01FA01, rituximab, Prazosin may increase the hypotensive activities of Rituximab.]
[S01FA01, atropine, Atropine may decrease the antihypertensive activities of Prazosin.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[G04BE10, avanafil, Prazosin may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Prazosin.]
[G04BD12, mirabegron, The therapeutic efficacy of Mirabegron can be decreased when used in combination with Prazosin.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L04AA31, teriflunomide, Teriflunomide may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Prazosin.]
[L01EX05, regorafenib, Regorafenib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Prazosin.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Prazosin.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Prazosin.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Prazosin is combined with Lercanidipine.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Prazosin.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Prazosin.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Prazosin.]
[L01EA05, ponatinib, Ponatinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Prazosin is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, The risk or severity of hypotension can be increased when Prazosin is combined with Bendroflumethiazide.]
[N02BA10, benorilate, The therapeutic efficacy of Prazosin can be decreased when used in combination with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.]
[M01AH01, celecoxib, The therapeutic efficacy of Prazosin can be decreased when used in combination with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Prazosin.]
[L01EC02, dabrafenib, Dabrafenib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[R02AX03, benzydamine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Benzydamine.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[J05AJ03, dolutegravir, The serum concentration of Prazosin can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of hypotension can be increased when Prazosin is combined with Bepridil.]
[C02KX05, riociguat, The risk or severity of hypotension can be increased when Prazosin is combined with Riociguat.]
[C02KX04, macitentan, The risk or severity of hypotension can be increased when Prazosin is combined with Macitentan.]
[N06AX26, vortioxetine, Vortioxetine may decrease the antihypertensive activities of Prazosin.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Prazosin is combined with Dapagliflozin.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Prazosin.]
[C07AB04, acebutolol, The risk or severity of hypotension can be increased when Prazosin is combined with Acebutolol.]
[S01ED02, betaxolol, The risk or severity of hypotension can be increased when Prazosin is combined with Betaxolol.]
[C02CC01, bethanidine, The risk or severity of hypotension can be increased when Prazosin is combined with Bethanidine.]
[N07XX08, tafamidis, The serum concentration of Prazosin can be increased when it is combined with Tafamidis.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Prazosin.]
[S01EE02, unoprostone, Prazosin may increase the hypotensive activities of Unoprostone.]
[N05AA04, acepromazine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Prazosin.]
[L01EF01, palbociclib, Palbociclib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01EX08, lenvatinib, The serum concentration of Prazosin can be increased when it is combined with Lenvatinib.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N05AX16, brexpiprazole, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Prazosin.]
[N05AX15, cariprazine, Cariprazine may decrease the antihypertensive activities of Prazosin.]
[M02AA25, aceclofenac, The therapeutic efficacy of Prazosin can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Acemetacin.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[J02AC05, isavuconazole, Isavuconazole may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01EB04, osimertinib, Osimertinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01ED03, alectinib, Alectinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[B01AC27, selexipag, The risk or severity of hypotension can be increased when Prazosin is combined with Selexipag.]
[G04CA01, alfuzosin, Prazosin may increase the hypotensive activities of Alfuzosin.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[M01AE16, alminoprofen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Alminoprofen.]
[L01XX52, venetoclax, Venetoclax may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N04BC01, bromocriptine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Prazosin.]
[C08CA01, amlodipine, The risk or severity of hypotension can be increased when Prazosin is combined with Amlodipine.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Prazosin is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazosin.]
[C07AA19, bupranolol, The risk or severity of hypotension can be increased when Prazosin is combined with Bupranolol.]
[N07BC01, buprenorphine, Buprenorphine may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N05BE01, buspirone, Buspirone may decrease the antihypertensive activities of Prazosin.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Prazosin is combined with Arsenic trioxide.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01XK03, rucaparib, Rucaparib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[A07EC04, balsalazide, The therapeutic efficacy of Prazosin can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Prazosin.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C09AA07, benazepril, The risk or severity of hypotension can be increased when Prazosin is combined with Benazepril.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Prazosin.]
[L01ED04, brigatinib, Brigatinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Prazosin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Prazosin is combined with Acetylcholine.]
[L01XX59, enasidenib, Enasidenib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01EF03, abemaciclib, Abemaciclib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C07AB07, bisoprolol, The risk or severity of hypotension can be increased when Prazosin is combined with Bisoprolol.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Prazosin.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Prazosin.]
[C07AA17, bopindolol, The risk or severity of hypotension can be increased when Prazosin is combined with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Prazosin is combined with Nesiritide.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Prazosin.]
[M01AB07, bumadizone, The therapeutic efficacy of Prazosin can be decreased when used in combination with Bumadizone.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Prazosin.]
[C09AA01, captopril, The risk or severity of hypotension can be increased when Prazosin is combined with Captopril.]
[L02BB05, apalutamide, The serum concentration of Prazosin can be increased when it is combined with Apalutamide.]
[C07AG02, carvedilol, The risk or severity of hypotension can be increased when Prazosin is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Prazosin.]
[N03AX24, cannabidiol, Cannabidiol may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of hypotension can be increased when Prazosin is combined with Celiprolol.]
[P01BA07, tafenoquine, The serum concentration of Prazosin can be increased when it is combined with Tafenoquine.]
[N03AX17, stiripentol, The excretion of Prazosin can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, Dacomitinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[M01AC05, lornoxicam, The therapeutic efficacy of Prazosin can be decreased when used in combination with Lornoxicam.]
[L01EX13, gilteritinib, Gilteritinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01XJ03, glasdegib, Glasdegib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C09AA08, cilazapril, The risk or severity of hypotension can be increased when Prazosin is combined with Cilazapril.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Prazosin.]
[S01ED05, carteolol, Prazosin may increase the hypotensive activities of Carteolol.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Prazosin.]
[N06BA14, solriamfetol, Solriamfetol may decrease the antihypertensive activities of Prazosin.]
[L01EN01, erdafitinib, The serum concentration of Prazosin can be increased when it is combined with Erdafitinib.]
[C09CA06, candesartan, The risk or severity of hypotension can be increased when Prazosin is combined with Candesartan.]
[L02BB06, darolutamide, The serum concentration of Prazosin can be increased when it is combined with Darolutamide.]
[C03BX03, cicletanine, The risk or severity of hypotension can be increased when Prazosin is combined with Cicletanine.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N07XX11, pitolisant, The risk or severity of adverse effects can be increased when Pitolisant is combined with Prazosin.]
[N04CX01, istradefylline, Istradefylline may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C03AA09, cyclothiazide, The risk or severity of hypotension can be increased when Prazosin is combined with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Prazosin.]
[N02CC08, lasmiditan, The serum concentration of Prazosin can be increased when it is combined with Lasmiditan.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Prazosin.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Prazosin.]
[N02CC06, eletriptan, Eletriptan may decrease the antihypertensive activities of Prazosin.]
[M01AH02, rofecoxib, The therapeutic efficacy of Prazosin can be decreased when used in combination with Rofecoxib.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Prazosin is combined with Clevidipine.]
[C01BD07, dronedarone, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Dronedarone.]
[C02AA06, methoserpidine, The risk or severity of hypotension can be increased when Prazosin is combined with Methoserpidine.]
[L01EH03, tucatinib, The serum concentration of Prazosin can be increased when it is combined with Tucatinib.]
[L01EX17, capmatinib, The serum concentration of Prazosin can be increased when it is combined with Capmatinib.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Prazosin is combined with Opicapone.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Prazosin.]
[M01AC04, droxicam, The therapeutic efficacy of Prazosin can be decreased when used in combination with Droxicam.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Prazosin.]
[M02AA27, dexketoprofen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Dexketoprofen.]
[C08CA17, levamlodipine, The risk or severity of hypotension can be increased when Prazosin is combined with Levamlodipine.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C03AA04, chlorothiazide, The risk or severity of hypotension can be increased when Prazosin is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The serum concentration of Prazosin can be increased when it is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Chlorpromazine.]
[C03BA04, chlorthalidone, The risk or severity of hypotension can be increased when Prazosin is combined with Chlorthalidone.]
[N02BA07, ethenzamide, The therapeutic efficacy of Prazosin can be decreased when used in combination with Ethenzamide.]
[N02BA03, choline salicylate, The serum concentration of Prazosin can be increased when it is combined with Choline salicylate.]
[N06BX18, vinpocetine, The risk or severity of hypotension can be increased when Prazosin is combined with Vinpocetine.]
[M01AB08, etodolac, The therapeutic efficacy of Prazosin can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Prazosin can be decreased when used in combination with Etofenamate.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Prazosin.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Prazosin is combined with Vericiguat.]
[L01EX21, tepotinib, Tepotinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[V03AF12, trilaciclib, The serum concentration of Prazosin can be increased when it is combined with Trilaciclib.]
[M01AE05, fenbufen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, The risk or severity of hypotension can be increased when Prazosin is combined with Fenoldopam.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Prazosin.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Prazosin.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Prazosin.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Prazosin.]
[H04AA02, dasiglucagon, The risk or severity of hypotension can be increased when Prazosin is combined with Dasiglucagon.]
[A02BA01, cimetidine, The serum concentration of Prazosin can be increased when it is combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of hypotension can be increased when Prazosin is combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Prazosin can be increased when it is combined with Sotorasib.]
[L01XA01, cisplatin, The serum concentration of Prazosin can be increased when it is combined with Cisplatin.]
[L04AA48, belumosudil, Belumosudil may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[P01CA03, fexinidazole, The serum concentration of Prazosin can be increased when it is combined with Fexinidazole.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Prazosin can be decreased when used in combination with Mefenamic acid.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Prazosin.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Prazosin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Prazosin can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, Clomipramine may decrease the antihypertensive activities of Prazosin.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Prazosin is combined with Clonidine.]
[J02AC06, oteseconazole, The serum concentration of Prazosin can be increased when it is combined with Oteseconazole.]
[N05AH02, clozapine, Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C02KB01, metyrosine, The risk or severity of hypotension can be increased when Prazosin is combined with Metyrosine.]
[M01AX13, proquazone, The therapeutic efficacy of Prazosin can be decreased when used in combination with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Prazosin.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Prazosin.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Prazosin.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Prazosin can be decreased when used in combination with Imidazole salicylate.]
[B01AC10, indobufen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Indobufen.]
[M01AH03, valdecoxib, The therapeutic efficacy of Prazosin can be decreased when used in combination with Valdecoxib.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Prazosin.]
[N02CC05, almotriptan, Almotriptan may decrease the antihypertensive activities of Prazosin.]
[M01AH04, parecoxib, The therapeutic efficacy of Prazosin can be decreased when used in combination with Parecoxib.]
[J02AC02, itraconazole, Itraconazole may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Prazosin is combined with Acyclovir.]
[M01AA06, kebuzone, The therapeutic efficacy of Prazosin can be decreased when used in combination with Kebuzone.]
[L01EA01, imatinib, Imatinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Prazosin.]
[S01EE03, bimatoprost, Prazosin may increase the hypotensive activities of Bimatoprost.]
[C08CA09, lacidipine, Prazosin may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, The serum concentration of Prazosin can be increased when it is combined with Lamotrigine.]
[N07BC04, lofexidine, The risk or severity of hypotension can be increased when Prazosin is combined with Lofexidine.]
[M01AB09, lonazolac, The therapeutic efficacy of Prazosin can be decreased when used in combination with Lonazolac.]
[M02AA31, loxoprofen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Loxoprofen.]
[C09AA03, lisinopril, The risk or severity of hypotension can be increased when Prazosin is combined with Lisinopril.]
[C08CA11, manidipine, The risk or severity of hypotension can be increased when Prazosin is combined with Manidipine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Prazosin.]
[C07AA14, mepindolol, The risk or severity of hypotension can be increased when Prazosin is combined with Mepindolol.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Prazosin is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Methoxyphenamine.]
[C03DA04, eplerenone, The risk or severity of hypotension can be increased when Prazosin is combined with Eplerenone.]
[C03AA07, cyclopenthiazide, The risk or severity of hypotension can be increased when Prazosin is combined with Cyclopenthiazide.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Prazosin.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Prazosin.]
[C09AA13, moexipril, The risk or severity of hypotension can be increased when Prazosin is combined with Moexipril.]
[M02AA02, mofebutazone, The therapeutic efficacy of Prazosin can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Prazosin can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Prazosin is combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of hypotension can be increased when Prazosin is combined with Moxonidine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Prazosin is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of hypotension and syncope can be increased when Vardenafil is combined with Prazosin.]
[M01AH05, etoricoxib, The therapeutic efficacy of Prazosin can be decreased when used in combination with Etoricoxib.]
[C02CC04, debrisoquin, The risk or severity of hypotension can be increased when Prazosin is combined with Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Prazosin is combined with Nabilone.]
[M01AX01, nabumetone, The therapeutic efficacy of Prazosin can be decreased when used in combination with Nabumetone.]
[C07AB12, nebivolol, The risk or severity of hypotension can be increased when Prazosin is combined with Nebivolol.]
[N06AX06, nefazodone, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.]
[C01DX16, nicorandil, The risk or severity of hypotension can be increased when Prazosin is combined with Nicorandil.]
[C01CA23, theodrenaline, Prazosin may decrease the hypertensive activities of Theodrenaline.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Prazosin.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Prazosin.]
[A07EC03, olsalazine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, The serum concentration of Prazosin can be increased when it is combined with Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Prazosin.]
[C09XA02, aliskiren, The risk or severity of hypotension can be increased when Prazosin is combined with Aliskiren.]
[M01AE12, oxaprozin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Oxaprozin.]
[S03BA01, dexamethasone, Dexamethasone may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Amphetamine.]
[B01AC04, clopidogrel, The serum concentration of Prazosin can be increased when it is combined with Clopidogrel.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Prazosin.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Prazosin.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Prazosin is combined with Diclofenamide.]
[S01BC03, diclofenac, The therapeutic efficacy of Prazosin can be decreased when used in combination with Diclofenac.]
[C02DG01, pinacidil, The risk or severity of hypotension can be increased when Prazosin is combined with Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Prazosin is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Prazosin is combined with Pipamperone.]
[L01EB02, erlotinib, Erlotinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Prazosin.]
[A08AA03, diethylpropion, The therapeutic efficacy of Prazosin can be decreased when used in combination with Diethylpropion.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C08CA03, isradipine, The risk or severity of hypotension can be increased when Prazosin is combined with Isradipine.]
[N02BA11, diflunisal, The therapeutic efficacy of Prazosin can be decreased when used in combination with Diflunisal.]
[C02DB01, dihydralazine, The risk or severity of hypotension can be increased when Prazosin is combined with Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may decrease the antihypertensive activities of Prazosin.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin.]
[B01AC21, treprostinil, The risk or severity of hypotension can be increased when Prazosin is combined with Treprostinil.]
[C08DB01, diltiazem, The risk or severity of hypotension can be increased when Prazosin is combined with Diltiazem.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Prazosin.]
[N02BB04, propyphenazone, The therapeutic efficacy of Prazosin can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Proglumetacin.]
[G02AD02, dinoprostone, The serum concentration of Prazosin can be increased when it is combined with Dinoprostone.]
[R06AA02, diphenhydramine, The serum concentration of Prazosin can be increased when it is combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of hypotension can be increased when Prazosin is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Prazosin.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Prazosin.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Prazosin.]
[C09AA05, ramipril, The risk or severity of hypotension can be increased when Prazosin is combined with Ramipril.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Prazosin.]
[C01BA03, disopyramide, The serum concentration of Prazosin can be increased when it is combined with Disopyramide.]
[N05AX08, risperidone, Prazosin may increase the hypotensive activities of Risperidone.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazosin.]
[L01EX01, sunitinib, Sunitinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[G04BE08, tadalafil, The risk or severity of hypotension can be increased when Prazosin is combined with Tadalafil.]
[S01BC05, ketorolac, The therapeutic efficacy of Prazosin can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, The risk or severity of hypotension can be increased when Prazosin is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Prazosin can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The therapeutic efficacy of Prazosin can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Prazosin.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Prazosin.]
[C01CA04, dopamine, The serum concentration of Prazosin can be increased when it is combined with Dopamine.]
[N06AA16, dothiepin, Dosulepin may decrease the antihypertensive activities of Prazosin.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Prazosin.]
[N06AA12, doxepin, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Prazosin.]
[N05AD08, droperidol, Droperidol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin.]
[C09AA11, spirapril, The risk or severity of hypotension can be increased when Prazosin is combined with Spirapril.]
[N02CC01, sumatriptan, Sumatriptan may decrease the antihypertensive activities of Prazosin.]
[C07AB13, talinolol, The risk or severity of hypotension can be increased when Prazosin is combined with Talinolol.]
[M01AC02, tenoxicam, The therapeutic efficacy of Prazosin can be decreased when used in combination with Tenoxicam.]
[G04CA03, terazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Terazosin.]
[G04BD05, terodiline, The risk or severity of hypotension can be increased when Prazosin is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of hypotension can be increased when Prazosin is combined with Tertatolol.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Prazosin.]
[N06AX14, tianeptine, Tianeptine may decrease the antihypertensive activities of Prazosin.]
[C09AA02, enalapril, The therapeutic efficacy of Prazosin can be increased when used in combination with Enalapril.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Prazosin can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Prazosin.]
[N06BA09, atomoxetine, Atomoxetine may decrease the antihypertensive activities of Prazosin.]
[C03CA04, torsemide, The risk or severity of hypotension can be increased when Prazosin is combined with Torasemide.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Prazosin.]
[C09AA10, trandolapril, The risk or severity of hypotension can be increased when Prazosin is combined with Trandolapril.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Prazosin.]
[C02CA06, urapidil, The risk or severity of hypotension can be increased when Prazosin is combined with Urapidil.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Prazosin.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Prazosin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Prazosin.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Prazosin.]
[C08CA12, mepirodipine, Prazosin may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Prazosin.]
[C09AA15, zofenopril, The risk or severity of hypotension can be increased when Prazosin is combined with Zofenopril.]
[M01AB04, zomepirac, The therapeutic efficacy of Prazosin can be decreased when used in combination with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of hypotension can be increased when Prazosin is combined with Zonisamide.]
[C02AC02, guanfacine, The risk or severity of hypotension can be increased when Prazosin is combined with Guanfacine.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Prazosin.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Prazosin.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Prazosin.]
[N02CA02, ergotamine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Ergotamine.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C01CA15, gepefrine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Gepefrine.]
[V03AF05, amifostine, Prazosin may increase the hypotensive activities of Amifostine.]
[N03AD01, ethosuximide, The risk or severity of hypotension can be increased when Prazosin is combined with Ethosuximide.]
[M01AC06, meloxicam, The therapeutic efficacy of Prazosin can be decreased when used in combination with Meloxicam.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Prazosin.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Prazosin.]
[N06AX12, bupropion, The excretion of Prazosin can be decreased when combined with Bupropion.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[A02BA03, famotidine, The serum concentration of Prazosin can be increased when it is combined with Famotidine.]
[C08CA02, felodipine, The risk or severity of hypotension can be increased when Prazosin is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypotension can be increased when Prazosin is combined with Fendiline.]
[M01AE04, fenoprofen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Prazosin.]
[N02AB03, fentanyl, Fentanyl may decrease the antihypertensive activities of Prazosin.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Prazosin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Prazosin is combined with Clofarabine.]
[N02BG04, floctafenine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Floctafenine.]
[N07CA03, flunarizine, The risk or severity of hypotension can be increased when Prazosin is combined with Flunarizine.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Prazosin.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Prazosin.]
[N05AF01, flupenthixol, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N05CD01, flurazepam, The serum concentration of Prazosin can be increased when it is combined with Flurazepam.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of hypotension can be increased when Prazosin is combined with Fluspirilene.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Prazosin.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Prazosin.]
[C03CA01, furosemide, The risk or severity of hypotension can be increased when Prazosin is combined with Furosemide.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Prazosin is combined with Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Prazosin is combined with Ganciclovir.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Prazosin.]
[L01EA02, dasatinib, Dasatinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N04BC06, cabergoline, Cabergoline may decrease the antihypertensive activities of Prazosin.]
[N03AD03, methsuximide, The risk or severity of hypotension can be increased when Prazosin is combined with Methsuximide.]
[N01AH02, alfentanil, Alfentanil may decrease the antihypertensive activities of Prazosin.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Prazosin.]
[C05AE01, nitroglycerin, The risk or severity of hypotension can be increased when Prazosin is combined with Nitroglycerin.]
[C02CA04, doxazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Doxazosin.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C07AB09, esmolol, The risk or severity of hypotension can be increased when Prazosin is combined with Esmolol.]
[C09AA09, fosinopril, The risk or severity of hypotension can be increased when Prazosin is combined with Fosinopril.]
[S01EX01, guanethidine, The risk or severity of hypotension can be increased when Prazosin is combined with Guanethidine.]
[N01AB01, halothane, Halothane may decrease the antihypertensive activities of Prazosin.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Prazosin.]
[C09CA01, losartan, The risk or severity of hypotension can be increased when Prazosin is combined with Losartan.]
[A07EC02, mesalamine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Mesalazine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Prazosin.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Prazosin.]
[J05AG01, nevirapine, The risk or severity of adverse effects can be increased when Nevirapine is combined with Prazosin.]
[C08CA10, nilvadipine, The risk or severity of hypotension can be increased when Prazosin is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Prazosin is combined with Nimesulide.]
[C09AA04, perindopril, The risk or severity of hypotension can be increased when Prazosin is combined with Perindopril.]
[C02DB02, hydralazine, The risk or severity of hypotension can be increased when Prazosin is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of hypotension can be increased when Prazosin is combined with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The risk or severity of hypotension can be increased when Prazosin is combined with Hydroflumethiazide.]
[G04BD06, propiverine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[C02AC06, rilmenidine, The risk or severity of hypotension can be increased when Prazosin is combined with Rilmenidine.]
[R02AX02, ibuprofen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Ibuprofen.]
[N01AH03, sufentanil, Sufentanil may decrease the antihypertensive activities of Prazosin.]
[N06AA02, imipramine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Prazosin is combined with Paclitaxel.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Prazosin.]
[C03BA11, indapamide, The risk or severity of hypotension can be increased when Prazosin is combined with Indapamide.]
[S01BC01, indomethacin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Indomethacin.]
[C02CA02, indoramin, The risk or severity of hypotension can be increased when Prazosin is combined with Indoramin.]
[S01XA28, varenicline, The serum concentration of Prazosin can be increased when it is combined with Varenicline.]
[C07AA01, alprenolol, The risk or severity of hypotension can be increased when Prazosin is combined with Alprenolol.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Prazosin.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Prazosin.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Prazosin.]
[S01EC03, dorzolamide, Prazosin may increase the hypotensive activities of Dorzolamide.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Prazosin.]
[C09AA16, imidapril, The risk or severity of hypotension can be increased when Prazosin is combined with Imidapril.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Prazosin.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Prazosin.]
[C01DA14, isosorbide mononitrate, Prazosin may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide dinitrate.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Prazosin.]
[C02KD01, ketanserin, The risk or severity of hypotension can be increased when Prazosin is combined with Ketanserin.]
[H02CA04, levoketoconazole, The serum concentration of Prazosin can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin.]
[M02AA10, ketoprofen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Ketoprofen.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Prazosin.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Prazosin.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Prazosin can be decreased when used in combination with Tiaprofenic acid.]
[C07AG01, labetalol, The risk or severity of hypotension can be increased when Prazosin is combined with Labetalol.]
[N04BB01, amantadine, The serum concentration of Prazosin can be increased when it is combined with Amantadine.]
[C02AA05, deserpidine, The risk or severity of hypotension can be increased when Prazosin is combined with Deserpidine.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Prazosin is combined with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Prazosin is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Prazosin is combined with Lidoflazine.]
[C03DB01, amiloride, The serum concentration of Prazosin can be increased when it is combined with Amiloride.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Prazosin.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Prazosin.]
[A07DA03, loperamide, The risk or severity of hypotension can be increased when Prazosin is combined with Loperamide.]
[V04CC02, magnesium sulfate, The risk or severity of hypotension can be increased when Prazosin is combined with Magnesium sulfate.]
[L01EA03, nilotinib, Nilotinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Prazosin is combined with Mannitol.]
[C02BB01, mecamylamine, The risk or severity of hypotension can be increased when Prazosin is combined with Mecamylamine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Prazosin can be decreased when used in combination with Meclofenamic acid.]
[C01CA11, mephentermine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Mephentermine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Prazosin.]
[N05AX13, paliperidone, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Prazosin.]
[N06BA03, methamphetamine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Metamfetamine.]
[J05AF05, lamivudine, The risk or severity of adverse effects can be increased when Prazosin is combined with Lamivudine.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Prazosin is combined with Methazolamide.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Prazosin.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Prazosin.]
[N02BG08, ziconotide, The risk or severity of hypotension can be increased when Prazosin is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Prazosin.]
[N02BG09, methoxyflurane, Methoxyflurane may decrease the antihypertensive activities of Prazosin.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Prazosin can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, The risk or severity of hypotension can be increased when Prazosin is combined with Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Prazosin.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Prazosin.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Prazosin.]
[N02CA04, methysergide, Methysergide may decrease the antihypertensive activities of Prazosin.]
[C03BA08, metolazone, The risk or severity of hypotension can be increased when Prazosin is combined with Metolazone.]
[C07AB02, metoprolol, The risk or severity of hypotension can be increased when Prazosin is combined with Metoprolol.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Prazosin.]
[N02BB03, aminopyrine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Aminophenazone.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Prazosin.]
[C09CA03, valsartan, The risk or severity of hypotension can be increased when Prazosin is combined with Valsartan.]
[D11AX01, minoxidil, The risk or severity of hypotension can be increased when Prazosin is combined with Minoxidil.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Lisdexamfetamine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Prazosin.]
[C01BD01, amiodarone, The risk or severity of hypotension can be increased when Prazosin is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Prazosin.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Prazosin.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Prazosin is combined with Silodosin.]
[N06AA17, amoxapine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.]
[C07AA12, nadolol, The risk or severity of hypotension can be increased when Prazosin is combined with Nadolol.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Prazosin.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Prazosin.]
[N06BA01, amphetamine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The therapeutic efficacy of Prazosin can be decreased when used in combination with Naproxen.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Prazosin is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Prazosin.]
[N01AH06, remifentanil, Remifentanil may decrease the antihypertensive activities of Prazosin.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Prazosin is combined with Levosimendan.]
[N05AX14, iloperidone, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Prazosin is combined with Amphotericin B.]
[C09CA07, telmisartan, The risk or severity of hypotension can be increased when Prazosin is combined with Telmisartan.]
[M04AA03, febuxostat, The excretion of Prazosin can be decreased when combined with Febuxostat.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Prazosin.]
[C08CA04, nicardipine, The risk or severity of hypotension can be increased when Prazosin is combined with Nicardipine.]
[C04AE02, nicergoline, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nicergoline.]
[N07BA01, nicotine, The serum concentration of Prazosin can be increased when it is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of hypotension can be increased when Prazosin is combined with Nifedipine.]
[M02AA17, niflumic acid, The therapeutic efficacy of Prazosin can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Prazosin is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of hypotension can be increased when Prazosin is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Prazosin is combined with Nisoldipine.]
[C08CA08, nitrendipine, The risk or severity of hypotension can be increased when Prazosin is combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Prazosin.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Prazosin is combined with Pramipexole.]
[C02DD01, nitroprusside, The risk or severity of hypotension can be increased when Prazosin is combined with Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Prazosin.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Prazosin.]
[C02KX01, bosentan, The risk or severity of hypotension can be increased when Prazosin is combined with Bosentan.]
[N06AA10, nortriptyline, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Prazosin.]
[A02BC01, omeprazole, Omeprazole may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Prazosin.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Prazosin.]
[G04CA02, tamsulosin, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Tamsulosin.]
[C07AA02, oxprenolol, The risk or severity of hypotension can be increased when Prazosin is combined with Oxprenolol.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Prazosin.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Prazosin can be decreased when used in combination with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Prazosin can be decreased when used in combination with Oxyphenbutazone.]
[V04CH30, 4-aminohippuric acid, The serum concentration of Prazosin can be increased when it is combined with Aminohippuric acid.]
[N05AH05, asenapine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Prazosin is combined with Pancuronium.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Prazosin is combined with Papaverine.]
[C02KC01, pargyline, The risk or severity of hypotension can be increased when Prazosin is combined with Pargyline.]
[C07AA23, penbutolol, The risk or severity of hypotension can be increased when Prazosin is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypotension can be increased when Prazosin is combined with Penfluridol.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Prazosin.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Prazosin.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Prazosin.]
[C08EX02, perhexiline, The risk or severity of hypotension can be increased when Prazosin is combined with Perhexiline.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Prazosin.]
[A10BA01, phenformin, The serum concentration of Prazosin can be increased when it is combined with Phenformin.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Prazosin.]
[C04AX02, phenoxybenzamine, The risk or severity of hypotension can be increased when Prazosin is combined with Phenoxybenzamine.]
[A08AA01, phentermine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, The risk or severity of hypotension can be increased when Prazosin is combined with Phentolamine.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Prazosin can be decreased when used in combination with Phenylbutazone.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Prazosin.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Prazosin.]
[C08CX01, mibefradil, The risk or severity of hypotension can be increased when Prazosin is combined with Mibefradil.]
[C07AA03, pindolol, The risk or severity of hypotension can be increased when Prazosin is combined with Pindolol.]
[J05AE01, saquinavir, Saquinavir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of hypotension can be increased when Prazosin is combined with Eprosartan.]
[S01BC06, piroxicam, The therapeutic efficacy of Prazosin can be decreased when used in combination with Piroxicam.]
[J01MA11, grepafloxacin, The serum concentration of Prazosin can be increased when it is combined with Grepafloxacin.]
[N02CX01, pizotyline, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.]
[C09CA04, irbesartan, The risk or severity of hypotension can be increased when Prazosin is combined with Irbesartan.]
[J05AE03, ritonavir, Ritonavir may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C07AB01, practolol, The risk or severity of hypotension can be increased when Prazosin is combined with Practolol.]
[C01DX02, prenylamine, The risk or severity of hypotension can be increased when Prazosin is combined with Prenylamine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Prazosin.]
[M04AB01, probenecid, The serum concentration of Prazosin can be increased when it is combined with Probenecid.]
[C01BA02, procainamide, The serum concentration of Prazosin can be increased when it is combined with Procainamide.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Prazosin.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Prazosin.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N05AA03, promazine, Promazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin.]
[C01BC03, propafenone, The risk or severity of hypotension can be increased when Prazosin is combined with Propafenone.]
[N05AC01, periciazine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Periciazine.]
[N05CM06, propiomazine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiomazine.]
[N01AX10, propofol, Propofol may decrease the antihypertensive activities of Prazosin.]
[C07AA05, propranolol, The risk or severity of hypotension can be increased when Prazosin is combined with Propranolol.]
[N02CC04, rizatriptan, Rizatriptan may decrease the antihypertensive activities of Prazosin.]
[B01AC09, epoprostenol, The risk or severity of hypotension can be increased when Prazosin is combined with Epoprostenol.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Prazosin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.]
[P01AX05, quinacrine, The serum concentration of Prazosin can be increased when it is combined with Quinacrine.]
[C01BA01, quinidine, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quinidine.]
[P01BC01, quinine, The serum concentration of Prazosin can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Prazosin can be increased when it is combined with Ranitidine.]
[C02AA01, rescinnamine, The risk or severity of hypotension can be increased when Prazosin is combined with Rescinnamine.]
[C02AA02, reserpine, The risk or severity of hypotension can be increased when Prazosin is combined with Reserpine.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Prazosin.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Prazosin.]
[N02BA05, salicylamide, The therapeutic efficacy of Prazosin can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Prazosin can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Prazosin can be decreased when used in combination with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Prazosin.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Prazosin.]
[L01FA03, obinutuzumab, Prazosin may increase the hypotensive activities of Obinutuzumab.]
[C07AA07, sotalol, The risk or severity of hypotension can be increased when Prazosin is combined with Sotalol.]
[L01CD04, cabazitaxel, Cabazitaxel may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Prazosin.]
